HYDROMORPHONE HP 20 20 MG
HYDROMORPHONE HYDROCHLORIDE : 20 MG · DIN 02145936 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is HYDROMORPHONE HP 20?
HYDROMORPHONE HP 20 20 MG contains HYDROMORPHONE HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02145936, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for SUBCUTANEOUS ; INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Aug-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYDROMORPHONE HP 20 used for?
Relief of severe pain in opioid-tolerant patients requiring high doses; supervised injectable opioid agonist therapy (siOAT) for severe opioid use disorder in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is HYDROMORPHONE HP 20 called?
The same molecule, HYDROMORPHONE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dilaudid | Latin | Australia |
| Hikma | Latin | Australia |
| Dilaudid-HP | Latin | Australia |
| HYDROMORPHONE JUNO | Latin | Australia |
| HYDROMORPHONE JUNO-HP | Latin | Australia |
| Hydromorphone-hameln | Latin | Australia |
| Hydromorphone-hameln-HP | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02145936 |
|---|---|
| Brand name | HYDROMORPHONE HP 20 |
| Generic / active ingredient | HYDROMORPHONE HYDROCHLORIDE : 20 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 20 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA03 HYDROMORPHONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Aug-2005 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02145936 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2145936 |
| Brand name | HYDROMORPHONE HP 20 |
| Active ingredient / INN | HYDROMORPHONE HYDROCHLORIDE : 20 MG |
| ATC code | N02AA03 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.08 |
| Health Canada schedule | NARCOTICS (CDSA I) |
| Biosimilar biologic | No |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
How is it administered?
Individualized dosing based on prior opioid use. Administer via SC, IV, or IM injection. siOAT must be supervised by experienced physicians in facilities equipped for resuscitation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text summary (refers to section 10 of full monograph).
How is it supplied?
Not explicitly detailed in the provided text summary (refers to section 12 of full monograph).
Which pack is which?
| Strength on the label | 20 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAMUSCULAR ; INTRAVENOUS |
| Packaging as described in the monograph | Not explicitly detailed in the provided text summary (refers to section 12 of full monograph). |
| Storage | Not explicitly detailed in the provided text summary (refers to section 10 of full monograph). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to hydromorphone; opioid-naive patients; GI obstruction; acute asthma; respiratory depression; acute alcoholism; head injury; MAO inhibitors; pregnancy/breast-feeding.
Warnings and precautions
High concentration: risk of fatal overdose if confused with lower concentrations. Risks of addiction, abuse, misuse, and life-threatening respiratory depression. Avoid alcohol.
Is HYDROMORPHONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02AA03 HYDROMORPHONE. 34 of 85 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROMORPHONE | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02364115 |
| APO-HYDROMORPHONE | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02364123 |
| APO-HYDROMORPHONE | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02364131 |
| APO-HYDROMORPHONE | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02364158 |
| DILAUDID | 1 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00705438 |
| DILAUDID | 2 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125083 |
| DILAUDID | 4 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00125121 |
| DILAUDID | 8 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 00786543 |
| HYDROMORPH CONTIN | 4.5 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359502 |
| HYDROMORPH CONTIN | 9 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02359510 |
Who else supplies HYDROMORPHONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYDROMORPHONE appears in 134 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does HYDROMORPHONE cost around the world?
HYDROMORPHONE is listed on 2 national price registers Nexara tracks, across 63 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 10 | 37 | 08 Sep 2026 |
| United States | acquisition | 10 | 26 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.